NEWTON CHARLES W. (Chief Financial Officer) received a stock award from LYELL IMMUNOPHARMA, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/26/2025ACC: 0001415889-25-005753
Officer· Chief Financial Officer
Since Jun 2021
+618.75K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
3
Total transactions
618.75K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+112.50K
Price / share
—
Trade value
—
% of position
186.8%
2/10/2025
60.23K→172.72K
Total
Net shares
+112.50K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/10/2025 | A · Award | +112.50K | — | — | 186.8% | 60.23K | 172.72K |
| Total | +112.50K | $0.00 | ||||||
Derivative Transactions2
Option (right to buy)
Direct
Converts to
Common Stock
450K shares
Shares
+450K
Strike price
0.5535
Held after
450K
Exercisable
—
2/10/2025
Option (right to buy)
Direct
Converts to
Common Stock
56.25K shares
Shares
+56.25K
Strike price
0.5535
Held after
56.25K
Exercisable
—
2/10/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Option (right to buy) Direct | Common Stock450K shares | 2/10/2025 | A · Award | +450K | 0.5535 | — | 450K |
| Option (right to buy) Direct | Common Stock56.25K shares | 2/10/2025 | A · Award | +56.25K | 0.5535 | — | 56.25K |